0A50 Stock Overview A molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Co-Diagnostics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Co-Diagnostics Historical stock prices Current Share Price US$0.73 52 Week High US$2.18 52 Week Low US$0.72 Beta -0.91 1 Month Change -29.80% 3 Month Change -40.90% 1 Year Change -37.60% 3 Year Change -92.84% 5 Year Change n/a Change since IPO -93.53%
Recent News & Updates
New minor risk - Profitability Nov 10
Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.20 loss in 3Q 2023) Nov 10
Co-Diagnostics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 26
Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.31 loss in 2Q 2023) Aug 11
Co-Diagnostics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 25
Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024 Jul 17 See more updates
New minor risk - Profitability Nov 10
Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.20 loss in 3Q 2023) Nov 10
Co-Diagnostics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 26
Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.31 loss in 2Q 2023) Aug 11
Co-Diagnostics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 25
Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024 Jul 17
Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform Jun 15
Full year 2023 earnings released: US$1.20 loss per share (vs US$0.45 loss in FY 2022) May 12
New minor risk - Shareholder dilution May 12
Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 27
Co-Diagnostics, Inc. Appoints Executive Appointments Apr 04
Full year 2023 earnings released: US$1.20 loss per share (vs US$0.45 loss in FY 2022) Mar 15
Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024 Mar 01
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro Dec 27
Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.043 loss in 3Q 2022) Nov 11
Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 27
High number of new and inexperienced directors Aug 30
Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer Aug 30
Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.083 loss in 2Q 2022) Aug 12
Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023 Jul 23
Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program Jul 14
High number of new and inexperienced directors Jul 05
First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.34 profit in 1Q 2022) May 14
Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023 May 06
High number of new and inexperienced directors May 06
Full year 2022 earnings released: US$0.45 loss per share (vs US$1.27 profit in FY 2021) Mar 17
Investor sentiment improved over the past week Jan 18
High number of new and inexperienced directors Jan 17
Investor sentiment deteriorated over the past week Dec 15
High number of new and inexperienced directors Nov 28
Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer Nov 02
Co-Diagnostics, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 28
Investor sentiment improved over the past week Oct 04
Pomerantz Law Firm Announces the Filing of a Class Action Against Co-Diagnostics, Inc. and Certain Officers Sep 20
Investor sentiment deteriorated over the past week Aug 18
Kaplan Fox & Kilsheimer LLP Files Class Action Suit in the United States District Court for the Southern District of New York Against Co-Diagnostics, Inc Aug 17
Second quarter 2022 earnings released: US$0.083 loss per share (vs US$0.34 profit in 2Q 2021) Aug 12
Co-Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 03
Investor sentiment improved over the past week Jul 29
Co-Diagnostics, Inc., Annual General Meeting, Aug 31, 2022 Jul 21
Investor sentiment improved over the past week Jul 06
Now 21% undervalued after recent price drop Jun 27
Now 22% undervalued after recent price drop Jun 10
Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus May 27
First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.28 in 1Q 2021) May 14
High number of new and inexperienced directors May 09
High number of new and inexperienced directors Apr 02
Investor sentiment improved over the past week Mar 18
Investor sentiment deteriorated over the past week Jan 24 Co-Diagnostics, Inc. (NasdaqCM:CODX) completed the acquisition of Advanced Conceptions, Inc.
Co-Diagnostics, Inc. (NasdaqCM:CODX) entered into an Agreement and Plan of Merger to acquire Idaho Molecular Inc. Dec 24
Investor sentiment improved over the past week Dec 22
Investor sentiment deteriorated over the past week Nov 24
Third quarter 2021 earnings released: EPS US$0.40 (vs US$0.56 in 3Q 2020) Nov 12
Co-Diagnostics, Inc. to Introduce at Home/Point of Care Device at AACC on Sept 28 Sep 29
Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy Sep 09
Second quarter 2021 earnings released: EPS US$0.34 (vs US$0.54 in 2Q 2020) Aug 13
Co-Diagnostics, Inc. Provides Earnings Guidance for the Third Quarter 2021 Aug 13
Investor sentiment improved over the past week Jul 23 Co-Diagnostics, Inc.(NasdaqCM:CODX) dropped from Russell 3000E Index
Co-Diagnostics, Inc Receives CE Marking for Direct Saliva SARS-CoV-2 Test Jun 19
Investor sentiment improved over the past week May 20
First quarter 2021 earnings released: EPS US$0.28 (vs US$0.047 loss in 1Q 2020) May 15
Co-Diagnostics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021 May 14
Investor sentiment deteriorated over the past week Apr 01
Full year 2020 earnings released: EPS US$1.59 (vs US$0.37 loss in FY 2019) Mar 28
Co-Diagnostics Provides Earnings Guidance for the First Quarter of 2021 Mar 27
Co-Diagnostics, Inc. to Report Q4, 2020 Results on Mar 25, 2021 Mar 19
Co-Diagnostics, Inc. Announces the Development of A New Point-Of-Care/At Home PCR Diagnostic Testing, Screening and Surveillance Platform Mar 03
Co-Diagnostics, Inc. Partner to Offer At-Home Saliva Collection Kits for CoPrimer™-Based Covid-19 PCR Test Through Walgreens Find Care® Feb 26
Investor sentiment deteriorated over the past week Feb 24
Co-Diagnostics, Inc. Announces CFO Chnages Feb 23
Investor sentiment improved over the past week Feb 05
Co-Diagnostics, Inc. Completes FDA EUA Submission for Extraction-Free Saliva COVID-19 Test Jan 29
Investor sentiment improved over the past week Jan 20
Independent Director recently sold US$127k worth of stock Jan 16
Investor sentiment deteriorated over the past week Jan 05
Co-Diagnostics, Inc. Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer Platform Dec 23
Independent Director recently sold US$172k worth of stock Dec 22
Co-Diagnostics, Inc.'s Joint Venture Cosara Diagnostics Pvt Ltd Receives Clearance from Central Drugs Standard Control Organization for COVID-19 2-Gene Multiplex Test Nov 26
Co-Diagnostics, Inc. Receives CE Markings for ABC and SARS-CoV-2 2-Gene Multiplex Tests Nov 18
Co-Diagnostics, Inc.'s CoPrimers™ Shown to be Effective in COVID-19 Saliva PCR Tests Without Sample Extraction Nov 12 Shareholder Returns 0A50 GB Medical Equipment GB Market 7D -7.9% -2.3% -2.2% 1Y -37.6% -10.6% 2.4%
See full shareholder returns
Return vs Market: 0A50 underperformed the UK Market which returned 2.4% over the past year.
Price Volatility Is 0A50's price volatile compared to industry and market? 0A50 volatility 0A50 Average Weekly Movement 6.9% Medical Equipment Industry Average Movement 6.5% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0A50 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0A50's weekly volatility (7%) has been stable over the past year.
About the Company Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.
Show more Co-Diagnostics, Inc. Fundamentals Summary How do Co-Diagnostics's earnings and revenue compare to its market cap? 0A50 fundamental statistics Market cap US$23.31m Earnings (TTM ) -US$41.28m Revenue (TTM ) US$7.32m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0A50 income statement (TTM ) Revenue US$7.32m Cost of Revenue US$3.71m Gross Profit US$3.61m Other Expenses US$44.89m Earnings -US$41.28m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.29 Gross Margin 49.30% Net Profit Margin -563.91% Debt/Equity Ratio 0%
How did 0A50 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 01:48 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Co-Diagnostics, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Yi Chen H.C. Wainwright & Co. James Sidoti Sidoti & Company, LLC
Show 0 more analysts 
